MYOCARDITIS AFTER COVID-19 M-RNA VACCINATION: A SYSTEMATIC REVIEW
Keywords:
Covid-19, Immunity, m-RNA, Myocarditis, VaccineAbstract
One of the possible solutions to the problem of COVID-19 is vaccination against the virus. Vaccination may provide immunity by stimulating the immune system of the receiver to mount a response to the antigens that are present inside the vaccine. As part of the immunological response, a person may have both local and systemic symptoms, such as discomfort at the injection site or fever. Additional components of the vaccination have the potential to cause responses. Myocarditis that was reported to VAERS after vaccination with mRNA-based COVID-19 had demographic characteristics that were comparable to those of cases of myocarditis that were not associated with vaccination. However, the acute clinical course of myocarditis that was reported to VAERS after vaccination was different from the acute clinical course of myocarditis that was reported in cases that were not associated with vaccination. The risk of myocarditis increased after getting immunizations based on mRNA for COVID-19 in all age and gender groups, with the risk being highest after the second immunization dose in male adolescents and young men. This danger has to be assessed in light of the many positive aspects associated with the COVID-19 vaccination. One of the many possible processes is a hyperimmune or inflammatory response after exposure to spike protein, mRNA strand, or an unexplained trigger. Another possibility is a delayed onset of hypersensitivity.
References
Gorbalenya AE. Severe acute respiratory syndrome-related coronavirus – The species and its viruses, a statement of the Coronavirus Study Group. BioRxiv. 2020;2(7):93–7.
Centers for Disease Control and Prevention. 2019 Novel Coronavirus (2019- nCoV). Washington DC; 2020.
Komite Penanganan COVID-19. Laporan Penambahan Jumlah Kasus COVID-19 di Indonesia. Jakarta; 2020.
SK Dirjen P2P No HK.02.02/4/1/2021. Keputusan Direktur Jenderal Pencegahan dan Pengendalian Penyakit Nomor HK.02.02/4/1/2021 Tentang Petunjuk Teknik Pelaksanaan Vaksinasi dalam Rangka Penanggulangan Pandemi Corona Virus Disease 2019 (COVID-19).
Cooper Jr LT. Myocarditis. N Engl J Med. 2009;360(15):1526–38.
Tschöpe C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. Maret 2021;18(3):169–93.
Engler RJM, Nelson MR, Collins LCJ, Spooner C, Hemann BA, Gibbs BT, et al. A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination. PLoS One. 2015;10(3):e0118283.
Aslan I, Fischer M, Laser KT, Haas NA. Eosinophilic myocarditis in an adolescent: a case report and review of the literature. Cardiol Young. April 2013;23(2):277– 83.
Zipes D, Libby P, Bonow R. Braunwald’s Heart Disease. 8 ed. Philadelphia: Elsevier; 2019.
Piras A, Melis G, Cugusi L, Bassareo PP. Myopericarditis in a Male Adolescent Following the Second Shot of COVID-19 Pfizer m-RNA Vaccine: Typical Example and Analysis of 110 Single Case Reports. Pediatr Rep. September 2022;14(4):401–9.
Elhouderi E, Elsawalhy E, Kabbani M. Myopericarditis After mRNA COVID-19 Vaccine in a Patient With Recent History of COVID-19. Vol. 14, Cureus. United States; 2022. hal. e25264.
Perez Y, Levy ER, Joshi AY, Virk A, Rodriguez-Porcel M, Johnson M, et al. Myocarditis Following Coronavirus Disease 2019 mRNA Vaccine: A Case Series and Incidence Rate Determination. Clin Infect Dis an Off Publ Infect Dis Soc Am. Agustus 2022;75(1):e749–54.
Kim HW, Jenista ER, Wendell DC, Azevedo CF, Campbell MJ, Darty SN, et al. Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol. Oktober 2021;6(10):1196–201.
Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, et al. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol. Oktober 2021;6(10):1202–6.
Navar AM, McNally E, Yancy CW, O’Gara PT, Bonow RO. Temporal Associations Between Immunization With the COVID-19 mRNA Vaccines and Myocarditis: The Vaccine Safety Surveillance System Is Working. Vol. 6, JAMA cardiology. United States; 2021. hal. 1117–8.
Nikolovski J, Koldijk M, Weverling GJ, Spertus J, Turakhia M, Saxon L, et al. Factors indicating intention to vaccinate with a COVID-19 vaccine among older US adults. PLoS One. 2021;16(5):e0251963.
Bozkurt B, Kamat I, Hotez PJ. Myocarditis With COVID-19 mRNA Vaccines. Circulation. Agustus 2021;144(6):471–84.
Vasudeva R, Bhatt P, Lilje C, Desai P, Amponsah J, Umscheid J, et al. Trends in Acute Myocarditis Related Pediatric Hospitalizations in the United States, 2007- 2016. Am J Cardiol. Juni 2021;149:95–102.
Arola A, Pikkarainen E, Sipilä JO, Pykäri J, Rautava P, Kytö V. Occurrence and Features of Childhood Myocarditis: A Nationwide Study in Finland. J Am Heart Assoc. November 2017;6(11).
Chou OHI, Mui J, Chung CT, Radford D, Ranjithkumar S, Evbayekha E, et al. COVID-19 vaccination and carditis in children and adolescents: a systematic review and meta-analysis. Clin Res Cardiol. Oktober 2022;111(10):1161–73.
Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation. Oktober 2006;114(15):1581–90.
Saji T, Matsuura H, Hasegawa K, Nishikawa T, Yamamoto E, Ohki H, et al. Comparison of the clinical presentation, treatment, and outcome of fulminant and acute myocarditis in children. Circ J. 2012;76(5):1222–8.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
